The National Institute for Health and Care Excellence (NICE) has issued a recommendation for a new treatment, efgartigimod alfa, for adults living with generalised myasthenia gravis. This decision means that the therapy could soon be available on the NHS for patients whose condition is not sufficiently managed by existing treatments.
Myasthenia gravis is a rare, chronic autoimmune disease that causes muscle weakness. It occurs when the immune system mistakenly attacks healthy tissues, specifically the connections between nerves and muscles. This attack disrupts the signals that allow muscles to contract, leading to symptoms such as drooping eyelids, double vision, difficulty swallowing, and weakness in the limbs. The severity of symptoms can fluctuate, making daily life challenging for many individuals.
Efgartigimod alfa, an intravenous treatment, targets a specific protein called the neonatal Fc receptor (FcRn). By blocking FcRn, the treatment helps to reduce the levels of harmful antibodies in the blood that are responsible for the muscle weakness seen in myasthenia gravis. Clinical trials have demonstrated its effectiveness in improving muscle strength and reducing disease symptoms in a significant proportion of patients.
Currently, standard treatments for myasthenia gravis include corticosteroids and other immunosuppressants, which aim to reduce the immune system's activity. While these treatments are effective for many, some patients do not achieve adequate control of their symptoms, leading to a persistent impact on their quality of life. The introduction of efgartigimod alfa offers a new, targeted option for this group of patients.
According to Myasthenia Gravis UK, an estimated 10,000 people in the UK are affected by myasthenia gravis, with around 1,000 new diagnoses each year. The condition can develop at any age, though it is more common in women under 40 and men over 60. The availability of new therapies like efgartigimod alfa is crucial for addressing the unmet needs within this patient community.
NICE's recommendation follows a thorough evaluation of the treatment's clinical effectiveness and cost-effectiveness. The organisation plays a vital role in determining which treatments are made available on the NHS in England and Wales, ensuring that patients have access to effective and value-for-money healthcare options.